Skip to Content

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma

TUESDAY, Dec. 8, 2020 -- For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to a study presented at the annual meeting of the American Society of Hematology, held virtually from Dec. 5 to 8.

Meletios A. Dimopoulos, M.D., from the National and Kapodistrian University of Athens in Greece, and colleagues conducted a multicenter study involving 304 patients with RRMM who had received one or more prior line of therapy, including lenalidomide (len) and proteasome inhibitor (PI) treatment. Patients were randomly assigned to the immunomodulatory drug pomalidomide and dexamethasone (Pd) with or without subcutaneous daratumumab (D-Pd).

After 190 progression-free survival (PFS) events, the primary analysis was performed. The researchers found that the study met its primary end point of improved PFS, with a hazard ratio of 0.63 (95 percent confidence interval. 0.47 to 0.85; P = 0.0018) for patients treated with D-Pd. For the D-Pd and Pd arms, the median PFS was 12.4 and 6.9 months, respectively. Complete response rates or better were 24.5 and 3.9 percent for D-Pd and Pd, respectively.

"Collectively, these data show that D-Pd is an effective and convenient treatment for patients with RRMM who received ≥1 prior therapy, including len and a PI," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Press Release

Abstract

More Information

© 2021 HealthDay. All rights reserved.

Posted: December 2020

Read this next

Triplet Therapy Slows Refractory Multiple Myeloma

WEDNESDAY, Nov. 18, 2020 -- A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a...

COVID-19 Case Fatality Rate 29 Percent in Multiple Myeloma Patients

WEDNESDAY, Aug. 5, 2020 -- For patients with multiple myeloma and COVID-19, the case fatality rate is 29 percent among hospitalized patients, with increased odds of adverse...

Low Vitamin D May Reduce Survival for Some With Multiple Myeloma

TUESDAY, April 28, 2020 -- Vitamin D deficiency is associated with reduced overall survival for patients with multiple myeloma (MM), with a differential effect across race,...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.